Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV. Issue 32 (31st July 2015)

• Record Type: Journal Article
• Authors: Gajdos, Vincent; Vidor, Emmanuel; Richard, Patrick; Tran, Clément; Sadorge, Christine
• Is Part Of: Vaccine. Volume 33:Issue 32(2015)
• Page Start: 3988
• Page End: 3996
• Publication Date: 2015-07-31
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.06.036
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Introduction</title> <p id="spar0005">This follow-up study assessed the 5-year persistence of vaccine-induced antibodies (Td-IPV or DT-IPV) and the immune response to a booster dose of DTaP-IPV.</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">This was an open-label, parallel-group (two arms), multicentre trial performed at 44 study sites in France. Children aged 11–13 years, of either sex, who received Td-IPV (Revaxis<sup>®</sup>) and DT-IPV (DT Polio<sup>®</sup>) vaccines at 6 years of age in one previous open-label trial with no further vaccination against diphtheria, tetanus, pertussis or poliomyelitis, were enrolled. All participants received a single intramuscular booster dose (0.5 mL) of DTaP-IPV vaccine (Tetravac-Acellulaire<sup>®</sup>). Study endpoints were based on antibody persistence and post-booster immune responses. Safety was monitored throughout the study. Descriptive statistics were used for all analyses.</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">Of the 758 children included in the previous study, 274 were included in this follow-up study; 129 had previously been vaccinated with Td-IPV, and 145 had previously received DT-IPV. At least 96.5% of participants in both groups presented an anti-diphtheria and anti-tetanus concentration ≥0.01 IU/mL, and anti-poliovirus types 1–3 titres ≥ 8 (1/dilution). Following vaccination with DTaP-IPV, anti-diphtheria and anti-tetanus antibody concentrations ≥0.1 IU/mL and anti-poliovirus types 1–3 antibody titres ≥8 (1/dilution) were achieved in all participants. DTaP-IPV was well tolerated in this study. There were no serious adverse events during the study, and no participant withdrew because of adverse events.</p> </sec> <sec> <title id="sect0025">Discussion</title> <p id="spar0020">The present study confirmed the long-term immunity conferred by Td-IPV when given as a booster dose, and supports the use of Td-IPV as a second booster at 6 years of age in children previously vaccinated against diphtheria, tetanus and poliomyelitis types 1–3.</p> </sec> </abstract>